Prostate Cancer Management: From Early Chemical Recurrence to HRPC (excluding Immunotherapy).
|
|
- Sharlene Sharp
- 6 years ago
- Views:
Transcription
1 Thanks to: The Medical Educator Consortium Luis Raez, MD, Florida International University 15th ed. Prostate Cancer Management: From Early Chemical Recurrence to HRPC (excluding Immunotherapy). Mayer Fishman, MD PhD Member, Moffitt Cancer Center Department of Genitourinary Oncology Professor, University of South Florida, Morsani College of Medicine Department of Oncologic Sciences Department of Internal Medicine
2 15 th Annual Miami Cancer Meeting
3 Visceral disease Local Low Risk* Local High Risk* Regional LN, SV Distant LN only Bone disease Symptomatic bone disease Cytopenias Lower impact and durability of conventional hormone therapy Symptomatic adenopathy *risk: Gleason grade # cores Gland size Capsule, SV PSA
4 Local therapy Local Low Risk* Local High Risk* Regional LN, SV No recurrence PSA only recurrence Region al LN
5 Local therapy Local Low Risk* Local High Risk* Regional LN, SV Distant, LN only Bone disease Visceral disease Symptomatic bone disease Cytopenias No recurrenc e PSA only recurren ce Regional LN Symptomatic adenopathy
6 Local therapy Local Low Risk* Local High Risk* Locally directed salvage therapy Regional LN, SV Distant, LN only Bone disease Visceral disease Symptomatic bone disease Cytopenias No recurrence PSA only recurrence Symptomati c adenopathy Regional LN
7
8 PTEN ETS-fusion No surprise: AR amplification P53: frequent
9
10 Sipuleucel-T ENZALUTAMIDE DOCETAXEL D CABAZITAXEL C S ABIRATERONE A A E APALUTAMIDE R RADIUM? New Immunotherapy Secondary Hormone Bone only Conventional Cytotoxic Chemotherapy Primary Hormone a- GnRH GnRH Degarelix goserelin leuprolide triptorelin XRT Prostate bed radiotherapy
11 CLINICAL STATES MODEL PCWG3
12 Sequencing: Not so simple mcrpc 1 st Line mcrpc 2nd Line mcrpc 3rd Line mcrpc 4th Line mcrpc 5th Line mcrpc 6th Line mcrpc 1 st Line mcrpc 2nd Line mcrpc 3rd Line mcrpc 4th Line mcrpc 5th Line S A R E D mcrpc C6th Line Also -- there is no reason to think there is only one best sequence, or that the same sequence is best for everyone
13 Real life is not as predictable as the diagrams. 91 d
14 Whole-body hormone changes Systemic vs intratumoral testosterone Intracellular testosterone and Androgen Receptor, and intranuclear Androgen receptor
15 Conventional hormonal axis: GnRH: Hypothalamus pituitary FSH: pituitary FSH secretion LH: pituitary LH secretion T: Circulating testosterone Leuprolide Goserelin Degarelix ADH Oxytocin 17-beta hydroxylase ketoconazole abiraterone AR/dihydroxytestosterone binding ACTH GH PRL TSH FSH LH ADRENAL Prostate Testes T CANCER
16 Androgen Receptor AR: single copy X chromosome allelic for CAG repeats (poly-q) 920 a.a. 9 exons >>> Splice variants <<< Cn3d: d/full.html?complexity=3&buidx=1&showse q=1&mmdbid= Ref:
17 Ref: Decoding the androgen receptor splice variants Changxue Lu, Jun Luo. Transl Androl Urol Sep; 2(3): exons 5 additional cryptic exons (CE) within introns
18 Radiographic PFS Enzalutamide
19 Abiraterone Radiographic PFS
20 Local therapy Local Low Risk Local High Risk Regional LN, SV Risk stratification Late, slow, low, no prior XRT: Consider for salvage bed XRT Late, slow: Observe vs hormone therapy Comorbid assessment No recurrence PSA only recurrence Not slow: GnRH therapy Comorbidity Long doubling time: (?) Doubling time < 10 months: SPARTAN (apalutamide) PROSPER (enzalutamide)
21 Age ~ y since dx DT < 10 mo 71% < 6 mo XRT: 77% GnRH: 97% Bica: 73% R mg apalutamide= 8 x30 mg/d placebo Check bone scan & CT scans every 16 weeks primary Secondary & exploratory Metastasis free survival HR = 0.28 None unmet Next slide
22
23 All secondary and exploratory endpoints met
24 C Sternberg EAU 10/2017 Median age 74 Median PSA: 11 DT < 10 mo 75% < 6 mo prostatectomy: 54% 933 R 468 Enzalutamide 4x40 = 160 mg placebo primary Secondary & exploratory Metastasis free survival HR = 0.29 Time to next treatment: HR =.21 Time to PSA progression HR =.07 >50% PSA decrease: 76 vs 2.4% >90% PSA decrease: 56 vs 0.4 % Undetectable PSA: 9.6 vs 0 % OS first eval (NS; not mature) HR = 0.80, P=.15
25 PROSPER: Rising PSA, M0, <10 mo DT AFFIRM: CRPC after chemotherapy PREVAIL: CRPC, before chemotherapy STRIVE (phase II), CRPC, before chemotherapy What is the best time to use enzalutamide?
26 AFFIRM mcrpc After chemotherapy 800 R 399 ENZALUTAMIDE Placebo OS PSA-PFS Radiographic PFS The study was stopped after a planned interim analysis.
27 PREVAIL mcrpc No prior chemotherapy R ENZALUTAMIDE 872 OS OS PSA-PFS 845 Placebo Radiographic-PFS No-chemotherapy PFS
28 STRIVE Rising PSA 257: mcrpc 139: CRPC (nm) No prior chemotherapy enzalutamide 198 R 198 PFS PFS bicalutamide
29 COUGAR 301: After chemotherapy COUGAR 302: CRPC, before chemotherapy STAMPEDE: At initial hormone therapy of metastatic disease LATITUDE: At initial hormone therapy of metastatic disease (phase II) Food effect food vs 1000/fasting
30 COUGAR 301 mcrpc After chemotherapy 797 R 398 abiraterone & prednisone Placebo & prednisone OS
31 COUGAR 302 mcrpc 546 abiraterone & prednisone No prior chemotherapy R 542 Placebo & prednisone * OS *44% received abiraterone after Other subsequent therapy 67% abiraterone 80% placebo group
32 LATITUDE US No prior hormone therapy for metastatic disease Start GnRH 597 R abiraterone & prednisone + Placebo & placebo
33 STAMPEDE EUROPE No prior hormone therapy for metastatic disease Start GnRH 960 R abiraterone & prednisone + Placebo & placebo
34 OS difference are driven by the HIGHER RISK subset of patients STAMPEDE
35 Small lowfat meal vs 750 mg abiraterone 4/7/18 CRPC N= 72 Phase II R 1000 (unfed) Food
36 Some negative taxane combinations phase III trials: Vitamin D receptor: Docetaxel with or without calcitriol VEGF: Docetaxel with or without bevacizumab VEGF: Docetaxel with or without ziv-aflibercept SRC: Docetaxel with or without dasatinib Vaccine: Docetaxel with or without GVAX
37 HSPC, m 397 R 393 Docetaxel x6 + GnRH Monotherapy GnRH OS difference are driven by the HIGHER RISK subset of patients
38 FIRSTANA Docetaxel 75 Cabazitaxel 25 Cabazitaxel 20 C20 v D75, HR =1.01 (95% CI, ) C25 v D75, HR =0.97 (95% CI, ) OS
39 ALSYMPCA OS Time-to-event Radium mcrpc 614 (Excludes: LN> 3 cm Visceral mets Cord compression) R 307 Placebo OS
40 ALSYMPCA OS Time-to-event OS difference are driven by the HIGHER RISK subset of patients
41 About ¼ CRPC should be eligible This limits accrual rates All are off-label DNA repair deficiency
42 The PARP proteins are part of the DNA repair complexes Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer Apr;10(4): Olaparib Rucaparib Niraparib par PARP ib inhibitor
43 NEJM
44 NEJM PARP directed prostate cancer trial examples: Olaparib vs enzalutamide vs abiraterone Olaparib before prostatatectomy Olaparib, abiraterone or both Olaparib with pembrolizumab Niraparib plus antiandrogen Niraparib with radium Rucaparib with cediranib Nivolumab + one of: rucaparib, docetaxel, enzalutamide
45 Conclusions (1/3) mcrpc 1 st Line mcrpc 2nd Line mcrpc 3rd Line mcrpc 4th Line mcrpc 5th Line All oral first; put off parenteral drugs Taxanes first save lower intensity treatment for older age Hormone therapy / non hormone therapy / hormone therapy alternation Hormone therapy salvage of hormone therapy only for slow progressors Radium as soon as bone-only pattern is seen Provenge as early as possible (metastasis, no pain, low PSA) Provenge in coordination with antiandrogen initiation Adaptive schedules: Alternate treatment and hiatus, to delay
46 Conclusions (2/3) What benefit for slower rising PSA? Hormone therapies beyond conventional GnRH: Active, but little empiric sequencing or crossover experience. apalutamide enzalutamide abiraterone Adapative vs continuous scheduling strategies Taxanes early, late, in-between? Radium be alert for optimal selection
47 Conclusions (3/3) Immune therapies sipuleucel-t and beyond Flucyclovine (Axumin) imaging to identify oligometastatic cases for radiation therapy Early concurrent hormone therapy for prostate bed salvage radiation therapy SINE inhibitor KPT-8602 trials
Updates in Prostate Cancer Treatment 2018
Updates in Prostate Cancer Treatment 2018 Mountain States Cancer Conference Elaine T. Lam, MD November 3, 2018 Learning Objectives Understand the difference between hormone sensitive and castration resistant
More informationAdvanced Prostate Cancer. November Jose W. Avitia, M.D
Advanced Prostate Cancer November 4 2017 Jose W. Avitia, M.D In 2017 161,000 new cases of prostate cancer diagnosed in US, mostly with elevated PSA 5-10% will present with metastatic disease In 2017: 26,000
More informationPROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute
PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis
More informationManagement of Incurable Prostate Cancer in 2014
Management of Incurable Prostate Cancer in 2014 Julie N. Graff, MD, MCR Portland VA Medical Center Assistant Professor of Medicine Knight Cancer Institute, OHSU 2014: Cancer Estimates Stage at Diagnosis
More informationPhilip Kantoff, MD Dana-Farber Cancer Institute
CHEMOTHERAPY FOR MCRPC Philip Kantoff, MD Dana-Farber Cancer Institute Harvard Medical School 1 Disclosure of Financial Relationships With Any Commercial Interest Name Nature of Financial Commercial Interests
More informationManagement of castrate resistant disease: after first line hormone therapy fails
Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Relevant Disclosure I have received research support
More informationManagement of castration resistant prostate cancer after first line hormonal therapy fails
Management of castration resistant prostate cancer after first line hormonal therapy fails Simon Crabb Senior Lecturer in Medical Oncology University of Southampton WHAT ARE THE AIMS OF TREATMENT? Cure?
More informationAdvanced Prostate Cancer
Advanced Prostate Cancer SAMO Masterclass 4 th March 2016 Aurelius Omlin Conflicts of interest Advisory Rolle: Astra Zeneca, Astellas, Bayer, Janssen, Pfizer, Sanofi Aventis Research support: TEVA, Janssen
More informationPerspective on endocrine and chemotherapy agents. Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy
Perspective on endocrine and chemotherapy agents Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy Disclosures Dr. Sternberg has received research funding for
More informationProstate Cancer. Dr. Andres Wiernik 2017
Prostate Cancer Dr. Andres Wiernik 2017 Objectives YES!!! 1. Epidemiology 2. Biology or Natural History of Prostate Cancer 3. Treatment NO!!! 1. Prostate Cancer Screening - controversies Which is the most
More informationGU Guidelines Update Meeting: M0 Castrate Resistant Prostate Cancer. Dr. Simon Yu Nov 18, 2017
GU Guidelines Update Meeting: M0 Castrate Resistant Prostate Cancer Dr. Simon Yu Nov 18, 2017 Faculty/Presenter Disclosure Faculty: Dr. Simon Yu Relationships with commercial interests: Grants/Research
More informationWhat will change for men with advanced prostate cancer in the next 24 months? ESO Observatory: Perspective on endocrine and chemotherapy agents
Perspective on endocrine and chemotherapy agents Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy Disclosures Dr.Sternberg has received research funding for
More informationIn autopsy, 70% of men >80yr have occult prostate ca
Prostate Cancer UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: Two randomized trials showed survival benefit of adding docetaxol to ADT in fit man with very high localized disease
More informationWhen exogenous testosterone therapy is. adverse responses can be induced.
Theoretical tips It has been reasoned that discontinuation of ADT in nonorchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release
More informationNew Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일
New Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일 Castrate-Resistant Prostate Cancer (CRPC) Current standard therapy Androgen receptor (AR) in CRPC New systemic therapies Hormonal therapy
More informationNovel treatment for castration-resistant prostate cancer
Novel treatment for castration-resistant prostate cancer Cora N. Sternberg, MD, FACP Chair, Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Treatment options for patients
More informationFrancesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
Prostata: Oral Communications Emerging strategies and controversial topics in advanced prostate cancer Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
More informationIndex Patients 3& 4. Guideline Statements 10/11/2014. Enzalutamide Reduced the Risk of Death
//4 Prolonged Radiographic Progression-Free Survival Reduced the Risk of Death Overall ITT Population Estimated median rpfs, months (9% CI): : NYR (.8 NYR); placebo:.9 (.7.4) rpfs (%) ( Enza 9 8 7 4 8
More informationJoelle Hamilton, M.D.
Joelle Hamilton, M.D. www.urologycentersalabama.com Case Presentation: CRPC, Rising PSA 70 yo healthy, fit, active man post RALP 8 years prior with rising PSA Rising PSA from 0.02 nadir to 3.4 thus ADT
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Abiraterone for the treatment of metastatic castration-resistant prostate cancer that has progressed on or after a docetaxel-based chemotherapy regimen Disease
More informationProstate cancer update: Dr Robert Huddart Cancer Clinic London
Prostate cancer update: 2013 Dr Robert Huddart Cancer Clinic London Recent developments Improved imaging New radiotherapy technologies Radiotherapy for advanced disease Intermittent hormone therapy New
More informationAdvanced Prostate Cancer. SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin
Advanced Prostate Cancer SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin aurelius.omlin@kssg.ch Conflicts of Interest Research Support: TEVA, Janssen Advisory Rolle: Astra Zeneca, Astellas,
More informationManagement of castrate resistant disease: after first line hormone therapy fails
Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Rhona McMenemin Consultant in Clinical Oncology The
More informationManagement of Prostate Cancer
Management of Prostate Cancer An ESMO Perspective Alan Horwich Conflicts of Interest Disclosure Alan Horwich I have no personal conflicts of interest relating to prostate cancer. European Incidence and
More informationUntil 2004, CRPC was consistently a rapidly lethal disease.
Until 2004, CRPC was consistently a rapidly lethal disease. the entry in systemic disease is declared on a an isolated PSA recurrence after local treatment so!!! The management of CRPC and MCRPC is different
More informationNCCN Guidelines for Prostate Cancer V Web teleconference 06/17/16 and 06/30/17
Guideline Page and Request PROS-1 Submission from Myriad Genetic Laboratories, Inc. Request addition of recommendation for genetic risk assessment/testing to the Initial Clinical Assessment algorithm for
More informationStrategic decisions for systemic treatment. metastatic castration resistant prostate cancer (mcrpc)
Strategic decisions for systemic treatment metastatic castration resistant prostate cancer (mcrpc) SAMO Luzern 14.09.2012 Richard Cathomas Onkologie Kantonsspital Graubünden richard.cathomas@ksgr.ch mcrpc
More informationSecond line hormone therapies. Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017
Second line hormone therapies Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017 Disclosures Institutional Research Support/P.I. Employee Consultant Major Stockholder Speakers
More informationSequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC)
Sequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC) Amit Bahl Consultant Oncologist Bristol Cancer Institute Clinical Director Spire Specialist Care Centre UK Disclosures Advisory
More informationSession 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy
Session 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy October- 2015 ESMO 2004 October- 2015 Fyraftensmøde 2 2010 October- 2015 Fyraftensmøde 3 SWOG 9916 OS
More informationHormone therapy works best when combined with radiation for locally advanced prostate cancer
Hormone therapy works best when combined with radiation for locally advanced prostate cancer Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Introduction Introduction 1/3 of patients
More informationGroup Sequential Design: Uses and Abuses
Group Sequential Design: Uses and Abuses Susan Halabi Department of Biostatistics and Bioinformatics, Duke University October 23, 2015 susan.halabi@duke.edu What Does Interim Data Say? 2 Group Sequential
More informationX, Y and Z of Prostate Cancer
X, Y and Z of Prostate Cancer Dr Tony Michele Medical Oncologist Prostate cancer Epidemiology Current EUA (et al) guidelines on Advanced Prostate Cancer Current clinical management in specific scenarios
More informationChallenging Cases. With Q&A Panel
Challenging Cases With Q&A Panel Case Studies Index Patient #1 Jeffrey Wieder, MD Case # 1 72 year old healthy male with mild HTN Early 2011: Preop bone scan and pelvic CT = no mets Radical prostatectomy
More informationSESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia
SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia Divisione di Oncologia Medica Unità Tumori Genitourinari SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract
More informationChemohormonal Therapy For Prostate Cancer. What is old, is new again!
Chemohormonal Therapy For Prostate Cancer What is old, is new again! Mount Tremblant January 20, 2017 Kala S. Sridhar MD, MSc, FRCPC Medical Oncologist, Princess Margaret Hospital Head, GU Medical Oncology
More informationMAMTA PARIKH, MD, MS CHALLENGING CASE #2: GU CANCER & STATE OF THE ART: CASTRATION RESISTANT PROSTATE CANCER
MAMTA PARIKH, MD, MS CHALLENGING CASE #2: GU CANCER & STATE OF THE ART: CASTRATION RESISTANT PROSTATE CANCER NO RELEVANT FINANCIAL RELATIONSHIPS IN THE PAST TWELVE MONTHS BY PRESENTER OR SPOUSE/PARTNER.
More informationUPDATE ON RECENT CUTTING-EDGE TRIALS: TREATMENTS NOW AVAILABLE FOR NEWLY DIAGNOSED mhspc PATIENTS
UPDATE ON RECENT CUTTING-EDGE TRIALS: TREATMENTS NOW AVAILABLE FOR NEWLY DIAGNOSED mhspc PATIENTS Dr. Neal Shore, Carolina Urologic Research Centre, USA Assoc. Prof. Neeraj Agarwal, Huntsman Cancer Institute,
More informationTreatment of Advanced Prostate Cancer
Treatment of Advanced Prostate Cancer Wm. Kevin Kelly, DO Associate Professor of Medicine and Surgery Yale University Yale University School of Medicine Advanced Prostate Cancer Metastatic Cancer Prostate
More informationPROSTATE CANCER Importance of Molecular Characteristics in Support of Therapeutic Decisions
PROSTATE CANCER Importance of Molecular Characteristics in Support of Therapeutic Decisions Outline Prognostic and diagnostic value of pathologic and molecular alterations in prostate cancer Current status
More informationAndrogens and prostate cancer: insights from abiraterone acetate and other novel agents
Androgens and prostate cancer: insights from abiraterone acetate and other novel agents Ian Davis Ludwig Institute for Cancer Research Austin Health, Melbourne, Australia Supported in part by an Australian
More information2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC
Ronald de Wit Erasmus MC Cancer Institute The Netherlands 2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC Disclosures Sanofi ; research grant support, consultancy and speaker fees Astellas;
More informationThe Current Prostate Cancer Landscape
A Phase 1-2 Dose-Escalation and Safety Study of ADXS-PSA Alone and of ADXS-PSA in Combination with KEYTRUDA (MK-3475) in Patients with Previously Treated Metastatic Castration-Resistant Prostate Cancer
More informationMETASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 /
METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / 2 0 1 8 Prostate Cancer- Statistics Most common cancer in men after a skin
More informationNew Treatment Options for Prostate Cancer
New Treatment Options for Prostate Cancer Moderator: Jeremy P. Goldberg, President, JPG Healthcare LLC Panelists: Philip Kantoff, MD, Director, Lank Center for Genitourinary Oncology, Dana- Farber Cancer
More informationThe Return of My Cancer -Emerging Effective Therapies Jianqing Lin, MD
Februray, 2013 The Return of My Cancer -Emerging Effective Therapies Jianqing Lin, MD Why/How my cancer is back after surgery and/or radiation? Undetected micro-metastatic disease (spreading) before local
More informationPLAATS VAN DE CHEMOTHERAPIE IN DE BEHANDELING VAN EEN PROSTAATCARCINOOM: EEN UPDATE. Daan De Maeseneer, Medisch Oncoloog
PLAATS VAN DE CHEMOTHERAPIE IN DE BEHANDELING VAN EEN PROSTAATCARCINOOM: EEN UPDATE Daan De Maeseneer, Medisch Oncoloog 1 Overview DEAT PSA/Tumor Burden METASTASES INITIAL DIAGNOSIS & THERAPY ADT CRP SREs/
More informationManagement of mcrpc: Hormonal therapy and treatment sequence for CRPC
Management of mcrpc: Hormonal therapy and treatment sequence for CRPC Professor Bertrand Tombal, MD, PhD Cliniques universitaires Saint-Luc Université catholique de Louvain Brussels, Belgium Credentials
More informationIncorporating New Agents into the Treatment Paradigm for Prostate Cancer
Incorporating New Agents into the Treatment Paradigm for Prostate Cancer Dr. Celestia S. Higano FACP, Professor, Medicine and Urology, Uni. of Washington Member, Fred Hutchinson Cancer Research Center
More informationOptimizing Outcomes in Advanced Prostate Cancer
Optimizing Outcomes in Advanced Prostate Cancer Module 3: Focus on Recent CRPC Guidelines and Advanced Hormone-Sensitive Disease Sébastien J. Hotte, MD, MSc (HRM), FRCPC Medical Oncologist and Head, Phase
More informationProstate Cancer in men with germline DNA repair deficiency
Prostate Cancer in men with germline DNA repair deficiency Bruce Montgomery, MD Professor, Medicine and Urology Univ Washington, Fred Hutchinson CRC VA Puget Sound HCS Disclosures Company Tokai, ESSA,
More informationAdvanced Prostate Cancer. Searching for Optimal Therapy Sequence and Assessing Emerging Treatment Options
Advanced Prostate Cancer Searching for Optimal Therapy Sequence and Assessing Emerging Treatment Options Disclaimer This slide deck in its original and unaltered format is for educational purposes and
More informationSIMPOSIO. Radioterapia stereotassica e nuovi farmaci nel tumore e della prostata metastatico
SIMPOSIO Radioterapia stereotassica e nuovi farmaci nel tumore e della prostata metastatico Definition of Oligometastatic PCa 1-3 synchronous metastases (bone and/or lymph nodes) 2-5 synchronous metastases
More informationA Forward Look at Options for. In Prostate Cancer
A Forward Look at Options for Prostate Cancer Charles J Ryan, MD Associate Professor of Medicine Helen Diller Family Comprehensive Cancer Center University of California, San Francisco UC 1 SF UC SF Castration
More informationSAMPLE ONLY. Your Health Matters. Advanced Prostate Cancer and its Treatment A Patient Guide. Please order from Documents and Media: 415/
Your Health Matters Advanced Prostate Cancer and its Treatment A Patient Guide UCSF Genitourinary Medical Oncology Program Charles Ryan, MD, UCSF Patient Advocates Please order from Documents and Media:
More informationAdvanced Prostate Cancer
Advanced Prostate Cancer January 13, 2017 Sindu Kanjeekal MD FRCPC Medical Oncology and Hematology Regional Systemic Quality Lead Erie St Clair Adjunct Professor Schulich School of Medicine and University
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationHormone sensitive prostate cancer To add abiraterone or docetaxel? Dr Lisa Pickering
> Hormone sensitive prostate cancer To add abiraterone or docetaxel? Dr Lisa Pickering Disclosures Institutional Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific
More informationHormonal Manipulations in CRPC. NW Clarke Professor of Urological Oncology Manchester UK
Hormonal Manipulations in CRPC NW Clarke Professor of Urological Oncology Manchester UK Standard Treatment of CRPC Pre 2004 (and in 2013?) PSA progression 99m Tc BS negative CT scan large lymph node component
More informationOngoing trials that might change the standard of care in mcrpc
Ongoing trials that might change the standard of care in mcrpc Igor Tsaur University Medicine Mainz COI Off-label use of drugs, devices, or other agents: none Data from IRB-approved human research is presented:
More informationSergio Bracarda MD, Medical Oncology, Dept. Of Oncology Az. Ospedaliera S. Maria, Terni; Italy. Milano, 2 marzo 2019
Sergio Bracarda MD, Medical Oncology, Dept. Of Oncology Az. Ospedaliera S. Maria, Terni; Italy Milano, 2 marzo 2019 My Disclosure Adv. Board Member for: Pfizer, BMS, Novartis, MSD, Roche, Genentech, Astellas,
More informationThe Role of the Medical Oncologist in the Treatment of Prostate Cancer. Alireza saadat hematologist and oncologist
The Role of the Medical Oncologist in the Treatment of Prostate Cancer Alireza saadat hematologist and oncologist When should you see an oncologist? High risk localized disease Rising PSA after local therapy
More informationWhen exogenous testosterone therapy is. adverse responses can be induced.
Theoretical tips It has been reasoned that discontinuation of ADT in non orchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release
More informationSecondary Hormonal therapies in mcrpc
Secondary Hormonal therapies in mcrpc Ravindran Kanesvaran Consultant,Division of Medical Oncology National Cancer Centre Singapore 1 Disclosures Research Support/P.I. Sanofi Consultant Major Stockholder
More informationESMO SUMMIT MIDDLE EAST 2018
ESMO SUMMIT MIDDLE EAST 2018 14 Years of progress in Prostate Cancer Standards of Care and new targets Name Ronald de Wit 6-7 April 2018, Dubai, UAE CONFLICT OF INTEREST DISCLOSURE Sub-title Sanofi Roche
More informationADT vs chemo + ADT as initial treatment for advanced prostate cancer
ADT vs chemo + ADT as initial treatment for advanced prostate cancer By Hussein Khaled Prof. Medical Oncology Cairo University Possible Levels of Prostate Cancer At Diagnosis Local-Regional Disease Spread
More information8/31/ ) Intermittent androgen deprivation in androgen-sensitive PCa. 1) Alpharadin (Ra223) in CRPC with bone metastases
Bruce J. Roth, M.D. Clinical Trials: Medivation, Oncogenix 1) Alpharadin (Ra223) in CRPC with bone metastases 2) Enzalutamide (MDV-31) in CRPC and prior docetaxel 3) Abiraterone in chemo-naïve CRPC 4)
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationDevelopmental Therapeutics for Genitourinary Malignancies
Developmental Therapeutics for Genitourinary Malignancies Russell Szmulewitz, MD April 2018 Disclosure Information 23 rd Annual Developmental Therapeutics Symposium Name of Speaker I have the following
More informationwww.drpaulmainwaring.com Figure 1 Androgen action Harris W P et al. (2009) Nat Clin Pract Urol doi:10.1038/ncpuro1296 Figure 2 Mechanisms of castration resistance in prostate cancer Harris W P et al. (2009)
More informationPatients Living Longer: The Promise of Newer Therapies
Patients Living Longer: The Promise of Newer Therapies David M. Nanus, MD! Chief, Division of Hematology and Medical Oncology! Weill Cornell Medicine! New York Presbyterian Hospital!! Demographics 180,890
More informationProstate Cancer 2009 MDV Anti-Angiogenesis. Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy. Docetaxel/Epothilone
Prostate Cancer 2009 Anti-Angiogenesis MDV 3100 Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy Docetaxel/Epothilone Abiraterone DC therapy Bisphosphonates Denosumab Secondary Hormonal
More informationAmerican Urological Association (AUA) Guideline
1 Approved by the AUA Board of Directors May 2018 Authors disclosure of potential conflicts of interest and author/staff contributions appear at the end of the article. 2018 by the American Urological
More informationSummary of Phase 3 IMPACT Trial Results Presented at AUA Meeting Webcast Conference Call April 28, Nasdaq: DNDN
Summary of Phase 3 IMPACT Trial Results Presented at AUA Meeting Webcast Conference Call April 28, 2009 Nasdaq: DNDN PROVENGE sipuleucel-t is an autologous active cellular immunotherapy that activates
More informationHave we optimized the use of Androgen Receptor pathway targeted drugs in Castrate-Resistant Prostate Cancer?
Have we optimized the use of Androgen Receptor pathway targeted drugs in Castrate-Resistant Prostate Cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to
More informationSUMMARY. 3. Emerging understanding of mechanisms of resistance to current treatments
SUMMARY 1. Discuss the active agents in prostate cancer currently available in Australia 2. Celebrate the growing role for Prostate Medical Oncologists in Multi Disc Teams active treaments overall survival
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationEarly Chemotherapy for Metastatic Prostate Cancer
Early Chemotherapy for Metastatic Prostate Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Smilow Cancer Center Yale University Medical Center Disclosure Consultant: Sanofi Aventis, Celgene,
More informationMetasta&c prostate cancer. Walid Obeid PGY IV SGHUMC
Metasta&c prostate cancer Walid Obeid PGY IV SGHUMC Defini&on Stage IV prostate cancer : is defined by the American Joint CommiEee on Cancer's TNM classifica&on system: T4, N0, M0, any prostate- specific
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationMichiel H.F. Poorthuis*, Robin W.M. Vernooij*, R. Jeroen A. van Moorselaar and Theo M. de Reijke
First-line non-cytotoxic therapy in chemotherapynaive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials Michiel H.F. Poorthuis*, Robin
More informationCancer de la prostate métastatique: prise en charge précoce
Cancer de la prostate métastatique: prise en charge précoce Stéphane Oudard, MD, PhD Georges Pompidou Hospital, Oncology Department, Paris, France stephane.oudard@egp.aphp.fr SAGB.CAB.14.08.0382c 3/02/2016
More informationDefinition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationNOVITÀ IN TEMA DI NEOPLASIA DELLA PROSTATA L ALGORITMO TERAPEUTICO NEL CARCINOMA DELLA PROSTATA METASTATICO SENSIBILE ALLA CASTRAZIONE
NOVITÀ IN TEMA DI NEOPLASIA DELLA PROSTATA L ALGORITMO TERAPEUTICO NEL CARCINOMA DELLA PROSTATA METASTATICO SENSIBILE ALLA CASTRAZIONE S.S. Oncologia Medica Genitourinaria Outline 1. Clinical case 2. Chemotherapy
More informationManagement of castrate resistant disease; after first line hormone therapy fails
Management of castrate resistant disease; after first line hormone therapy fails Dr. Syed A Hussain Clinical Senior Lecturer and Consultant in Medical Oncology University of Liverpool and Clatterbridge
More informationConvegno Nazionale AIOM Giovani 2016: News in Oncology. Daniele Alesini. Istituto Nazionale dei Tumori Regina Elena
Convegno Nazionale AIOM Giovani 2016: News in Oncology Daniele Alesini Istituto Nazionale dei Tumori Regina Elena Something Old Something New Something Borrowed Something Blue DOCETAXEL: BACK AND FORTH
More informationProstate Cancer: Vision of the Future By: H.R.Jalalian
1 H. R. Jalalian Hematologist&Oncologist Baqiyatallah University of Medical Sciences 2 State of the art: vision on the future Diagnosis Surgery Radiotherapy Medical Oncology 3 Early Detection PSA sensitivity
More informationNon metastatic castrate-resistant prostate cancer (M0 CRPC) Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Non metastatic castrate-resistant prostate cancer (M0 CRPC) Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards/honorarium for: Amgen, Astellas,
More informationCancer de la prostate: best of 2016
Cancer de la prostate: best of 2016 Dr Christophe Massard GR2016, 3 DEC 2016 Disclosure Participation to advisory boards, speaker or investigator for: Amgen, Astellas, Astra Zeneca, Bayer, Celgene, Genentech,
More informationEvolution or revolution in the treatment of prostate cancer
Evolution or revolution in the treatment of prostate cancer de Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Professor of Experimental Cancer Medicine Department of Medicine/ Drug Development Unit
More informationCurrent UW/SCCA GU Oncology Clinical Trials Updated 01/25/2010
Neoadjuvant Non-Metastatic Current UW/SCCA GU Oncology Clinical Trials Gleason Stage PSA Design Type Route Active surveillance PASS 3 Active Surveillance for pts w/ Active T1 2 NA Visit Seattle q6 months
More informationOligometastasis. Körperstereotaxie bei oligo-metastasiertem Prostatakarzinom wann und wie in Kombination mit Systemtherapie?
Körperstereotaxie bei oligo-metastasiertem Prostatakarzinom wann und wie in Kombination mit Systemtherapie? Daniel M. Aebersold 09. Dezember 2016 Oligometastasis JCO, 1995 1 Oligometastasis: Chance for
More informationCurrent role of chemotherapy in hormone-naïve patients Elena Castro
Current role of chemotherapy in hormone-naïve patients Elena Castro Spanish National Cancer Research Centre Lugano, 17 October 2017 Siegel, Ca Cancer J Clin,2017 Buzzoni, Eur Urol, 2015 -Aprox 15-20% of
More informationImmunotherapy and new agents in CRPC. Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Immunotherapy and new agents in CRPC Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards/honorarium for: Amgen, Astellas, Astrazeneca, Bayer, Clovis,
More informationSYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223
SYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223 ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 4-5 October 2018 Disclosures Participation in advisory boards:
More informationProstate Cancer Panel. June 2018
Prostate Cancer Panel June 2018 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending, future cash
More informationmajority of the patients. And taking an aggregate of all trials, very possibly has a modest effect on improved survival.
Hello. I am Farshid Dayyani. I am Assistant Professor in Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center. We will be talking today about prostate cancer for survivorship
More informationLower Baseline PSA Predicts Greater Benefit From Sipuleucel-T
Lower Baseline PSA Predicts Greater Benefit From Sipuleucel-T Schelhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater
More informationQoL compared with ADT plus placebo. perc considered this to be reasonable in the nmcrpc setting, where patients QoL is expected to be relatively high and stable. perc discussed that there is a net clinical
More information